▟ Vinebot intrinsic value, daily

← back

ZTS Zoetis

pharma · valued with opus medium conviction · deep-dived 2026-11-03

STRONG BUY
Intrinsic value$81.67
Price (at call)$83.18
Margin of safety -1.8%
vs market (rating basis) +46.0%

Zoetis is a mature but dominant animal-health franchise, priced near fair value after the rebound.

The story

Zoetis is the global leader in animal health, with a broad portfolio across companion animals and livestock, strong vet relationships, and pricing power from products that pet owners rarely trade down from. It is a mature franchise: growth has slowed as pet ownership normalizes after the pandemic and competitors push into dermatology and parasiticides, but its scale, R&D pipeline, and diversified portfolio still produce high, durable margins and strong cash flow.

No material facts have changed since 2026-09-30. TTM revenue of 9.52B and a 36.9% margin are in line with the slow-growth, high-margin story, so I'm keeping every driver. The target margin stays slightly below the current 37% to allow for competitive pressure on key franchises (Apoquel/Cytopoint, Simparica), and the 7-year horizon reflects a mature leader rather than a long-runway compounder.

Value drivers

Revenue growth (Y1)3.5%
Terminal growth3.0%
Forecast horizon7y
Target operating margin35.0%
Years to target margin5
Sales-to-capital0.77
Beta1.00
Failure probability2.0%
Cost of capital (WACC)8.5%
Terminal WACC8.5%

Valuation bridge

PV of explicit FCFF13.33B
PV of terminal value27.83B
Equity value33.75B
÷ shares → per share$81.67

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 9.85B 3.5% 36.5% 2.86B 432.59M 2.43B 2.24B
2 10.19B 3.4% 36.1% 2.93B 437.07M 2.49B 2.12B
3 10.53B 3.3% 35.8% 2.99B 440.98M 2.55B 2.00B
4 10.87B 3.2% 35.4% 3.06B 444.29M 2.61B 1.89B
5 11.21B 3.2% 35.0% 3.12B 446.96M 2.68B 1.78B
6 11.56B 3.1% 35.0% 3.22B 448.98M 2.77B 1.70B
7 11.90B 3.0% 35.0% 3.31B 450.32M 2.86B 1.62B

Key risks

  • Competitive entrants and biosimilars eroding dermatology and parasiticide franchises
  • Safety concerns or slower uptake of the Librela/Solensia osteoarthritis pain franchise
  • Slowing vet visit volumes and pressure on pet owners' spending

Catalysts

  • New product launches and label expansions that revive companion-animal growth
  • Capital returns (buybacks) at depressed multiples, plus steady margin delivery

History

DatePriceIntrinsicMoSRating
2026-11-03$83.18 $81.67 -1.8% STRONG BUY
2026-09-30$70.30 $78.26 +11.3% STRONG BUY
2026-08-27$77.52 $87.43 +12.8% STRONG BUY
2026-07-27$75.35 $86.88 +15.3% STRONG BUY
2026-06-23$76.84 $81.80 +6.5% STRONG BUY